Type 1 diabetes exaggerates features of Alzheimer's disease in APP transgenic mice
- 18 November 2009
- journal article
- Published by Elsevier BV in Experimental Neurology
- Vol. 223 (2), 422-431
- https://doi.org/10.1016/j.expneurol.2009.11.005
Abstract
No abstract availableKeywords
This publication has 55 references indexed in Scilit:
- Neurofibrillary and neurodegenerative pathology in APP-transgenic mice injected with AAV2-mutant TAU: neuroprotective effects of CerebrolysinActa Neuropathologica, 2009
- Defective insulin signaling pathway and increased glycogen synthase kinase‐3 activity in the brain of diabetic mice: Parallels with Alzheimer's disease and correction by insulinJournal of Neuroscience Research, 2008
- Neuroprotective Effects of Regulators of the Glycogen Synthase Kinase-3β Signaling Pathway in a Transgenic Model of Alzheimer's Disease Are Associated with Reduced Amyloid Precursor Protein PhosphorylationJournal of Neuroscience, 2007
- Tau Is Hyperphosphorylated at Multiple Sites in Mouse Brain In Vivo After Streptozotocin-Induced Insulin DeficiencyDiabetes, 2006
- Alzheimer‐like changes in protein kinase B and glycogen synthase kinase‐3 in rat frontal cortex and hippocampus after damage to the insulin signalling pathwayJournal of Neurochemistry, 2006
- Diabetes and Alzheimer's Disease - Is There a Connection?The Review of Diabetic Studies, 2006
- Lithium, a Common Drug for Bipolar Disorder Treatment, Regulates Amyloid-β Precursor Protein ProcessingBiochemistry, 2004
- APP processing is regulated by cytoplasmic phosphorylationThe Journal of cell biology, 2003
- Brain insulin and insulin receptors in aging and sporadic Alzheimer's diseaseJournal of Neural Transmission, 1998
- Neuropathological stageing of Alzheimer-related changesActa Neuropathologica, 1991